Angle Outlines Strategy As It Nears Major Regulatory Announcements

With approvals looming over the next few months, Angle spoke to Medtech Insight to probe deeper about its presentation at the 2021 Jefferies Healthcare Conference.

• Source: Alamy

Angle’s core strategy is “all about getting the best sample,” Angle CEO Andrew Newland explained at the 2021 Jefferies Healthcare Conference on 17 November. 

“Cancer is heterogenous; it’s dynamic,” he said, explaining that for each individual patient, their disease will progress at different rates, with different side effects. “Each patient’s cancer is different from...

More from In Vitro Diagnostics

More from Diagnostics